Buried alive: a novel approach to cancer treatment
Authors:
- 1 January 2004
- journal article
- Published by Wiley in The FASEB Journal
- Vol. 18 (1) , 1-4
Abstract
The heightened interest in the development of novel anti‐cancer drugs that trigger apoptotic death in cancer cells stems from the fact that immediately upon execution of the death signal, the corpse is efficiently removed via specific recruitment of phagocytic cells. This prevents spilling of cellular contents and the associated inflammatory response, a likely scenario during necrotic death. Recent evidence has established that phagocytic removal of apoptotic cells is a function of ligand–receptor interaction, whereby the ligand(s) for the scavenger receptor(s) of phagocytic cells is/are specifically expressed on apoptosing cells. Therefore, by implication, enhancing this ligand–receptor interaction could be an alternate means for removing unwanted cells. Here we present a provocative hypothesis that circumvents the need for chemother‐ apy‐induced apoptosis in cancer cells. According to our model, cancer cells need not die in order to be removed by scavenger cells, but could still be effectively phagocytosed provided the cell surface expression of specific molecules that strongly engage phagocytic cells is sufficiently enhanced. In other words, inducing the expression of “ eat me ” signals on cancer cells could be a novel approach to “bury alive” these unwanted cells without the untoward effects of chemotherapy‐induced apoptosis.—Fadeel, B., Orrenius, S., Pervaiz, S. Buried alive: a novel approach to cancer treatment.—Fadeel, B., Orrenius, S., Pervaiz, S. Buried alive: a novel approach to cancer treatment. FASEB J. 18, 1–4 (2004)Keywords
This publication has 18 references indexed in Scilit:
- Apoptotic Cells Induce Migration of Phagocytes via Caspase-3-Mediated Release of a Lipid Attraction SignalCell, 2003
- A blast from the past: clearance of apoptotic cells regulates immune responsesNature Reviews Immunology, 2002
- Anti-Cancer Drugs of Today and Tomorrow: Are we Close to Making the Turn from Treating to Curing Cancer?Current Pharmaceutical Design, 2002
- Apoptosis disables CD31-mediated cell detachment from phagocytes promoting binding and engulfmentNature, 2002
- Apoptosis and cancer chemotherapyTrends in Cell Biology, 2001
- Horizontal transfer of oncogenes by uptake of apoptotic bodiesProceedings of the National Academy of Sciences, 2001
- A receptor for phosphatidylserine-specific clearance of apoptotic cellsNature, 2000
- Selective cleavage of nuclear autoantigens during CD95 (Fas/APO-1)-mediated T cell apoptosis.Journal of Experimental Medicine, 1996
- CD36 gene transfer confers capacity for phagocytosis of cells undergoing apoptosis.Journal of Experimental Medicine, 1995
- Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes.Journal of Experimental Medicine, 1994